English Journal
- Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
- Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K.SourceDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. hirohitokobayashi-jua@umin.ac.jp
- Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2011 Aug;60(8):1075-84. doi: 10.1007/s00262-011-1021-7. Epub 2011 Apr 26.
- Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase I/II clinical trial of the adoptive transfer of γδ T cells to patients with advanced renal cell carcinoma. Eleven patients who had undergone nephrectomy and had lung
- PMID 21519826
- Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
- Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H.SourceDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. hirohitokobayashi-jua@umin.ac.jp
- Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2007 Apr;56(4):469-76. Epub 2006 Jul 19.
- PURPOSE: Although various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell carcinoma (RCC), adoptive immunotherapy using gamma-delta (gammadelta) T cells has not yet been tried. In this study, we designed a pilot study of adoptive immunotherapy usin
- PMID 16850345
- Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
- Gratama JW, Schmitz PI, Goey SH, Lamers CH, Stoter G, Bolhuis RL.SourceDepartment of Clinical and Tumor Immunology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
- International journal of cancer. Journal international du cancer.Int J Cancer.1996 Jan 17;65(2):152-60.
- We treated 72 patients with metastatic renal-cell cancer according to 2 protocols consisting of two 5-week induction cycles of continuous i.v. high-dose interleukin-2 (IL-2), i.m. interferon-alpha (IFN alpha) and ex vivo IL-2-activated lymphocytes, followed for patients with stable disease (SD), par
- PMID 8567110
Japanese Journal
- 全身多発転移をきたした心臓原発血管肉腫の1例―過去20年間の本邦肺転移症例報告30例の検討を含めて―
- 宮本 牧,高森 幹雄,村田 研吾,和田 暁彦,藤田 明
- 肺癌 50(2), 186-193, 2010
- … 受診，両肺に多発結節影を指摘された．CTで両肺，肝臓，左腸骨，右心房に腫瘤性病変を認めた．左腸骨のCTガイド下生検と右歯肉腫瘤の生検組織より血管肉腫と診断した．化学療法（docetaxel），免疫療法（teceleukin），局所放射線治療を行ったが，入院80日目に肺出血による呼吸不全のため死亡した．病理解剖では右心房原発低分化型血管肉腫を確認した．結論．過去の報告例も含め肺転移を起こしてからの予後は，平 …
- NAID 130000252355
- rIL-2製剤にて薬疹(紅斑)を呈した悪性血管内皮細胞腫の1例
- 小原 宏之,林 大海,森 弘樹,梅田 整,秦 維郎
- Skin cancer : official organ of the Japanese Society for Skin Cancer = 皮膚悪性腫瘍研究会機関誌 15(3), 280-283, 2000-12-25
- … So we continued rIL-2 therapy with teceleukin by one shot arterial injection. … We suspected drug eruptions which were caused by teceleukin.Erythema is well known as one of the side effects of rIL-2. …
- NAID 10025716421
Related Pictures
★リンクテーブル★
| リンク元 | 「テセロイキン」 |
「テセロイキン」
- 英
- teceleukin
- 商
- イムネース
- 関
- インターロイキン2
- 抗悪性腫瘍薬;遺伝子組換えIL-2製剤